Harbour BioMed, a Cambridge, MA, Rotterdam, NL, and Suzhou CN-based global, clinical stage biopharmaceutical company, completd its Series C financing of $102.8M.
DCM, a Menlo Park, Calif. – based early-stage global venture capital firm, closed its latest family of funds, totaling $880m.
CF PharmTech, Inc., a Suzhou, China-based maker of inhalation products, raised US $50M in Series F financing.
Zuoyebang, a Beijing, China-based online education technology company, raised $750M in funding.
Hutchison China MediTech Limited (Nasdaq/AIM: HCM) sold US$100m of shares at a price equivalent to US$25.00 per American Depositary Share via a private placement to General Atlantic, a global growth equity firm.
Geek+, a Beijing, China-based global provider of advanced robotics for logistics, closed its Series C funding round at over USD $200m in early 2020.
Immvira Group Company, a Shenzen, China-based biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, closed a $58m Series B financing.
VEsoft Inc., the Hangzhou, China-based developer of the Nebula Graph™ database, raised $8M in a series pre-A funding round.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, closed a $20m Series A financing of Zentera Therapeutics, a biopharmaceutical company with headquarters in Shanghai, China.
DataGrand, a Chinese AI startup that offers Natural Language Processing and RPA service to major enterprises in the nation, closed its CNY 270m (USD 38m) B+ funding round.
Pillar Biosciences, a Natick, Mass.- and Shanghai, China-based NGS clinical cancer diagnostics company, closed a $29.7m Series C financing.
Fourier Intelligence, a Shanghai, China-based robotics startup, completed a Series B+ funding round in excess of tens of milions of yuan.
Points Technology, a Chinese blockchain and AI startup, raised a multi-million US dollar worth Series A financing.
RemeGen, a Yantai, China-based biopharmaceutical company, closed an approximately USD $100m private financing round.
Technology giant Tencent Holdings Limited (00700.HK) launched a US$100 million Global Anti-Pandemic Fund to support international efforts against COVID-19.